Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Erratum: Oncolytic viruses get a boost with first FDA-approval recommendation

The Original Article was published on 01 June 2015

Nature Reviews Drug Discovery 14, 369–371 (2015)

In Table 1 of this article, the name of the oncolytic virus being developed by DNAtrix should have read 'DNX-2401'. This has been corrected in the online version of the article.

Authors

Additional information

The online version of the original article can be found at 10.1038/nrd4643

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Dolgin, E. Erratum: Oncolytic viruses get a boost with first FDA-approval recommendation. Nat Rev Drug Discov 14, 510 (2015). https://doi.org/10.1038/nrd4680

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd4680

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing